

Supporting Information

Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series

Christine Dahlke*, Jasmin Heidepriem, Robin Kobbe, René Santer, Till Koch, Anahita Fathi, My L. Ly, Stefan Schmiedel, Peter H. Seeberger, ID-UKE COVID-19 study group, Marylyn M. Addo*, Felix F. Loeffler*

Flow cytometry

Flow cytometry was used to analyze B-cell phenotype of immune cells. Cryopreserved PBMCs were isolated and stained using the following antibodies.

Table S1. Antibodies used for flow cytometry

Product	Company	Clone
B-cell panel		
Zombie Aqua live/dead	Biolegend	-
CD19 BUV395	BD	SJ25C1
CD3 APC-Cy7	Biolegend	SK7
CD24 BV605	Biolegend	ML5
CD27 BV711	Biolegend	O323
CD38 BV421	Biolegend	HIT2

Patient Material

Blood from four patients and one healthy control were collected at the University Medical Center Hamburg-Eppendorf. Donors provided written informed consent. The protocol was approved by the Ethics Committee of the Hamburg Medical Association, Germany. Peripheral blood mononuclear cells (PBMCs) were isolated and cryopreserved from EDTA-blood using standard operating procedures via Ficoll density gradient centrifugation. Serum samples were aliquoted and stored at -80°C.

Peptide microarrays

The whole proteome of SARS-CoV-2 (GenBank ID: MN908947.3) was mapped as overlapping sequences on peptide microarrays. The sequences of ORF1ab polyprotein, spike glycoprotein (S), ORF3a protein, envelope protein (E), membrane glycoprotein (M), ORF6 protein, ORF7a protein, ORF8 protein, nucleocapsid phosphoprotein (N), and ORF10 protein were elongated and linked by neutral GSGSGSG linkers to avoid truncated peptides. The elongated protein sequences were

translated into 4 883 different 15 amino acid peptides printed in duplicate (9 766 peptide spots) with a peptide-peptide overlap of 13 amino acids for high resolution epitope data. Peptide microarrays were obtained from PEPperPRINT GmbH (Heidelberg, Germany).

Processing and analysis of peptide microarrays

Before incubation of the serum samples, the arrays were pre-swollen for 15 min with 1.6 mL PBST (0.05 % (v/v) Tween 20 in PBS) at room temperature and orbital shaking at 100 rpm. To avoid nonspecific binding of the serum proteins, the arrays were incubated with blocking buffer (MB-070, Rockland Immunochemicals Inc., Limerick, USA) for 30 min at 100 rpm and room temperature. After short washing with PBST, 1.6 mL of sera, diluted 1:200 in staining buffer (10 % (v/v) blocking buffer in PBST), were incubated overnight at 100 rpm and 4 °C. To remove unbound serum components, the arrays were washed quickly three times with PBST. The human serum antibody classes IgG, IgM and IgA were detected with fluorescently labeled secondary antibodies: 0.5 mg/ml anti-human IgG-Fc fragment cross-adsorbed DyLight 680 conjugated (A80-304D6, Bethyl Laboratories, Montgomery, USA), 1.0 mg/ml anti-human IgM (mu chain) DyLight 549 conjugated (609-142-007, Rockland Immunochemicals Inc., Limerick, USA), 1.0 mg/ml anti-human IgA (alpha chain) antibody DyLight 800 conjugated (609-145-006, Rockland Immunochemicals Inc., Limerick, USA). The HA control peptides on the array were detected with 1.0 mg/ml anti-HA-peptide antibody (RT028, Bio X Cell, New Hampshire, USA) labeled with Lightning-Link Rapid Dylight 680 (327-0010, Innova Biosciences Ltd., Cambridge, United Kingdom). The secondary antibodies were diluted in staining buffer (anti-human IgG 1:1 000, anti-human IgA 1:1 600, anti-human IgM 1:2 000 and anti-HA-peptide 1:2 000) and applied to the microarrays for 30 min at 100 rpm at room temperature in the dark. To remove unbound secondary antibodies, the arrays were washed quickly three times with PBST. Finally, the arrays were dipped in 1 mM Tris HCl pH 7.4 and dried in a jet of air. The arrays were scanned and fluorescence signals were detected at 700 nm and 800 nm using an Odyssey Scanner (LI-COR Biotechnology Inc., Lincoln, Nebraska, USA) and at 532 nm with a Genepix 4000B (Molecular Devices, San José, USA). Analysis of the scans was performed using PepSlide Analyzer software (SICASYS Software GmbH, Heidelberg, Germany).

Table S2. Number of reactive SARS-CoV-2 peptides at different time points targeted by IgA and IgG antibodies of patients #1 – #4. Data derived from peptide microarray data, showing hits for ORF1ab polyprotein, spike glycoprotein, and all proteins.

IgA	Patient ID Days after onset of symptoms	Number of peptides above threshold (99.9th percentile of healthy control sample*)									
		#1			#2			#3	#4		#5
		d6	d10	d22	d3	d15	d24	d12	d4	d11	Control
Protein	ORF1ab polyprotein	3	20	67	10	2	0	18	167	79	5
	Spike glycoprotein	0	1	24	2	1	0	0	21	9	0
	ORF3a protein	0	0	0	0	0	0	4	8	0	0
	Envelope protein	0	0	0	1	1	0	1	0	0	0
	Membrane glycoprotein	0	1	4	0	0	0	1	0	0	0
	ORF6 protein	0	0	0	0	0	0	1	1	0	0
	ORF7a protein	0	0	0	0	0	0	0	4	1	0
	ORF8 protein	0	0	6	0	0	0	0	10	8	0
	Nucleocapsid phosphoprotein	0	1	7	0	1	0	0	3	0	0
	ORF10 protein	0	0	0	0	0	0	0	0	0	0
	Total	3	23	108	13	5	0	25	214	97	5

IgG	Patient ID Days after onset of symptoms	Number of peptides above threshold (99.9th percentile of healthy control sample*)									
		#1			#2			#3	#4		#5
		d6	d10	d22	d3	d15	d24	d12	d4	d11	Control
Protein	ORF1ab polyprotein	5	3	11	7	3	1	1	6	3	2
	Spike glycoprotein	2	4	7	1	0	0	0	3	0	0
	ORF3a protein	0	0	0	0	0	0	1	1	1	2
	Envelope protein	0	0	0	0	0	0	0	0	0	0
	Membrane glycoprotein	1	1	4	0	0	0	0	1	1	1
	ORF6 protein	0	0	0	0	0	0	0	0	0	0
	ORF7a protein	0	0	0	0	0	0	0	0	0	0
	ORF8 protein	0	0	0	0	0	0	0	0	0	0
	Nucleocapsid phosphoprotein	3	7	6	0	0	0	2	0	0	0
	ORF10 protein	0	0	0	0	0	0	0	0	0	0
	Total	11	15	28	8	3	1	4	11	5	5

IgM	Patient ID Days after onset of symptoms	Number of peptides above threshold (99.5th percentile of healthy control sample*)									
		#1			#2			#3	#4		#5
		d6	d10	d22	d3	d15	d24	d12	d4	d11	Control
Protein	ORF1ab polyprotein	2	2	3	21	1	1	20	19	18	23
	Spike glycoprotein	0	0	8	0	0	0	0	0	1	1
	ORF3a protein	0	0	0	0	0	0	1	1	0	1
	Envelope protein	1	1	1	1	0	0	0	0	0	0
	Membrane glycoprotein	0	0	0	0	0	0	0	0	0	0
	ORF6 protein	0	0	0	1	0	0	0	0	0	0
	ORF7a protein	0	0	0	0	0	0	0	0	0	0
	ORF8 protein	0	0	0	0	0	0	0	0	0	0
	Nucleocapsid phosphoprotein	0	0	1	0	0	0	0	0	0	0
	ORF10 protein	0	0	0	0	0	0	0	0	0	0
	Total	3	3	13	23	1	1	21	20	19	25

Table S3. Positive SARS-CoV-2 peptides in IgG, IgA, and IgM response for the spike glycoprotein, membrane glycoprotein, and nucleocapsid phosphoprotein.

Spike glycoprotein (S)					
IgG		IgA		IgM	
Position	Peptide	Position	Peptide	Position	Peptide
		45-59	SSVLHSTQDLFLPFF	45-59	SSVLHSTQDLFLPFF
		63-91	TWFHAIHVSGTNGTKRFDNPV LPFNDGVY		
		125-181	NVVIKVCEFCNDPFLGVYYH KNNKSWMESEFRVYSSANNC TFEYVSPFLMDLEG		
		215-229	DLPQGFSALEPLVDL		
		241-265	LLALHRSYLTPGDSSSGWTAGA AAY	241-265	LLALHRSYLTPGDSSSGWTAGA AAY
		271-295	QPRTFLLKYNENGTITDAVDCA LDP		
369-383	YNSASFSTFKCYGVS	343-357	NATRFASVYAWNRRK		
		415-429	TGKIADYNYKLPDDF		
		449-463	YNYLYRFRKSNLKP		
		565-587	FGRDIADTTDAVRDPQTLEILD		
		605-619	SNQVAVLYQDVNCTE		
637-651	STGSNVFQTRAGCLI	647-665	AGCLIGAEHVNNNSYECDIP		
725-739	EILPVSMTKTSVDCT	721-735	SVTTEILPVSMTKTS		
811-831	KPSKRSFIEDLLFNKVTLADA	809-827	PSKPSKRSFIEDLLFNKVT		
927-955	FNSAIGIKQDLSSTASALGKLQ DVVNQN	835-851	KQYGDCLGDIARDLIC		
		1087-1111	AHFPREGVFSVNGTHWFVTQ RNFYE		
		1131-1145	GIVNNTVYDPLQPEL	1127-1141	DVIGIVNNTVYDPL
1201-1217	QELGKYEQYIKWPWYIW	1193-1215	LNESLIDLQELGKYEQYIKWPW Y	1143-1157	PELDSFKEELDKYFK

Membrane glycoprotein (M)			
IgG		IgA	
Position	Peptide	Position	Peptide
1-7	MADSNGT	1-25	MADSNGTITVEELKKLLEQWN LVIG
203-222	NYKLNTDHSSSDNIALLVQ		

Nucleocapsid phosphoprotein (N)					
IgG		IgA		IgM	
Position	Peptide	Position	Peptide	Position	Peptide
		96-110	GGDGKMKDLSRWFYF		
		156-170	AIVLQLPQGTTLPKG		
176-206	SRGGSQASSRSSSRNSSRNS TPGSSRGTS	182-196	ASSRSSSRNSSRN	182-196	ASSRSSSRNSSRN
		236-262	GKGQQQQGQVTKKSAEAS KKPRQKR		
		276-298	RRGPEQTQGNFGDQELIRQGT DY		
366-382	TEPKKDKKKKADETQAL	332-346	TYTGAIKLDDKDPNF		
392-406	VTLPAADLDDFSKQ	380-394	QALPQRQKKQQTIVL		




Figure S1. Evolution of reactive SARS-CoV-2 peptides at different time points targeted by IgA (left) and IgG (right) antibodies of patient #4 (moderate symptoms, non-hospitalized).




Figure S2. Number of reactive SARS-CoV-2 peptides at different time points targeted by IgA and IgG antibodies of patient #4. Data derived from peptide microarrays, showing hits for all proteins, ORF1ab polyprotein, and spike glycoprotein.